AcquisitionsMay 4, 2026, 04:17 PM
Phoenix Asia to Acquire ACEA Pharma for $1B; Issues $20M Note
AI Summary
Phoenix Asia Holdings Limited announced a significant strategic move to acquire 100% of ACEA Pharma, Inc., a clinical-stage pharmaceutical company, for $1 billion in newly-issued ordinary shares. This acquisition, expected to close in Q2 2026, will transform Phoenix Asia from a substructure works company into a pharmaceutical-industry holding company. Additionally, the company issued a $20 million convertible promissory note to its controlling stockholder for advisory services, convertible at $10.00 per share.
Key Highlights
- Phoenix Asia to acquire 100% of ACEA Pharma, Inc., a clinical-stage pharmaceutical company.
- Acquisition consideration involves 100,000,000 newly-issued ordinary shares of Phoenix Asia.
- The agreed value of the acquisition shares is $1,000,000,000.00.
- The acquisition is expected to close in the second quarter of 2026, subject to regulatory approvals.
- Phoenix Asia issued a convertible promissory note with a principal sum of $20,000,000.00.
- The note was issued to the controlling stockholder and is convertible into ordinary shares at $10.00 per share.
- Post-acquisition, Phoenix Asia intends to transform into a pharmaceutical-industry holding company.